fluorouracil has been researched along with Actinic Keratosis in 162 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topical Fluorouracil 5% cream (5-FU) and 20% aminolevulinic acid (ALA)/ photodynamic therapy (PDT) are both FDA approved for the treatment of Actinic Keratosis (AK)." | 9.20 | A Controlled Comparison Study of Topical Fluourouracil 5% Cream Pre-Treatment of Aminolevulinic Acid/Photodynamic Therapy for Actinic Keratosis. ( Hamann, C; Tanghetti, EA; Tanghetti, M, 2015) |
| "Five per cent 5-fluorouracil (5-FU) cream is a well-established treatment for actinic keratosis (AK), and ingenol mebutate gel (IMB) is a novel topical field-directed therapy." | 9.20 | Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. ( Samorano, LP; Sanches, JA; Torezan, LA, 2015) |
| "The purpose of this study was to compare the efficacy of 5-fluorouracil (5-FU) with that of other treatments of actinic keratosis (AK)." | 9.01 | Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: A network meta-analysis. ( Cai, L; Li, Q; Tang, N; Wu, Y, 2019) |
| "Background Topical 5-fluorouracil (5-FU) is an antineoplastic antimetabolite used for the treatment of actinic keratosis." | 8.93 | 5-Fluorouracil-induced exacerbation of rosacea. ( Cohen, PR; Haddock, ES, 2016) |
| "5%/salicylic acid 10% (5-FU/SA) topical solution has been included in the National Italian portfolio for lesion-directed treatment of grade I/II actinic keratosis (AKs) located on the face or scalp." | 7.96 | Treatment monitoring of 5-fluorouracil 0.5%/salicylic acid 10% lesion-directed therapy for actinic keratosis using dermoscopy and in-vivo reflectance confocal microscopy. ( Benati, E; Condorelli, A; Cornacchia, L; Guiducci, L; Lai, M; Longo, C; Mirra, M; Pampena, R; Pellacani, G; Peris, K; Raucci, M, 2020) |
| "We identified 5700 subjects who filled prescriptions for 5-fluorouracil or imiquimod for treatment of actinic keratosis in 2007." | 7.91 | Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study. ( Asgari, MM; Chren, MM; Friedman, GD; Neugebauer, R; Sokil, M; Su, KA; Zhu, Z, 2019) |
| "To assess the RCM accuracy, sensibility and specificity for actinic keratosis, considering as a gold standard the histopathological examination; as well as to evaluate the efficacy of 5% 5-fluorouracil treatment." | 7.88 | In vivo Confocal Laser Microscopy for monitoring of actinic keratosis treatment: a comparison with histopathologic assessment after treatment with topical 5% 5-fluorouracil. ( Hirata, SH; Ishioka, P; Lellis, RF; Maia, M; Rodrigues, SB, 2018) |
| "5%/salicylic acid 10% (5-FU/SA) in the treatment of isolated hyperkeratotic actinic keratosis lesions in Spain." | 7.81 | Cost-effectiveness analysis of 5-fluorouracil 0.5%/salicylic acid 10% in the treatment of actinic keratosis in Spain. ( Brosa, M; Ferrándiz, C; Nieves, D; Plazas, MJ; Puig-Peiró, R, 2015) |
| "Actinic keratosis is a lesion that develops in sun-exposed areas of the skin and is considered to be a precancerous condition or an early in situ squamous cell carcinoma." | 7.01 | Evaluating the Efficacy and Safety of 4% 5-Fluorouracil Cream in Patients with Actinic Keratosis: An Expert Opinion. ( Bégeault, N; Delarue, A; Heppt, MV; Stockfleth, E, 2023) |
| " 4% 5-FU qd q4wks recorded 65 adverse events and 30% application site skin irritation versus 71 events and 60% with 5% 5-FU bid q4wks." | 6.82 | Efficacy, Safety, and Tolerability of 4% 5-Fluorouracil Cream in a Novel Patented Aqueous Cream Containing Peanut Oil Once Daily Compared With 5% 5-Fluorouracil Cream Twice Daily: Meeting the Challenge in the Treatment of Actinic Keratosis. ( Dohil, MA, 2016) |
| "At 6-month posttreatment follow-up, recurrence of cleared lesions (no clinically visible lesions in treatment area) occurred in 39." | 6.80 | A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. ( Dirschka, T; Dominicus, R; Karl, L; Rodríguez, R; Simon, JC; Willers, C, 2015) |
| "5-Fluorouracil (5-FU) is an antineoplastic agent that is used topically to treat actinic keratoses." | 5.62 | Painful scrotal dermatitis secondary to topical 5-fluorouracil. ( Himes, RS; McKee, PH; Roberts, AA; Smith, RJ; Yi, JZ, 2021) |
| "Topical 5-fluorouracil (5-FU) is used to treat actinic keratosis, although side effects limit treatment." | 5.51 | Short-Term Follow-Up of a Randomized Controlled Trial of 0.5% and 5% 5-Fluorouracil After Microneedling for Treatment of Facial Actinic Keratoses. ( Bakos, RM; Kalil, CLPV; Reinehr, CPH, 2022) |
| " cSCC chemoprevention activity of sunscreen and 5-fluorouracil-based (5-FU) actinic keratosis (AK) treatments has been demonstrated in randomized controlled trials (RCTs) in immunocompetent populations but not in OTRs." | 5.51 | Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments). ( Ahmed, I; Bowden, SJ; Gaunt, C; Gaunt, P; Green, AC; Harwood, CA; Hasan, ZU; Hogan, S; Homer, V; Ismail, F; Jefferson-Hulme, Y; Kentley, J; Lear, JT; Matin, RN; Milligan, A; Mitchell-Worsford, L; Proby, CM; Thomson, J; Van-de-Velde, V; Wheatley, K; Whitmarsh, T, 2022) |
| "A number of effective treatments for actinic keratosis are available, including topical and lesion-directed therapies." | 5.36 | Case-based experience in the use of 5-fluorouracil cream 0.5% as monotherapy and in conjunction with glycolic acid peels for the treatment of actinic keratosis. ( Goldberg, DJ, 2010) |
| "At 12 months after the end of treatment in patients with multiple actinic keratosis lesions on the head, 5% fluorouracil cream was the most effective of four field-directed treatments." | 5.30 | Randomized Trial of Four Treatment Approaches for Actinic Keratosis. ( Arits, AHMM; Essers, BAB; Jansen, MHE; Kelleners-Smeets, NWJ; Kessels, JPHM; Kouloubis, N; Mosterd, K; Nelemans, PJ; Quaedvlieg, PJF; Steijlen, PM; van Pelt, HPA, 2019) |
| "A prospective analysis was performed using data from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial, a randomized, double-blinded, placebo-controlled trial of topical 5-fluorouracil for chemoprevention of KC." | 5.30 | Effects of increased actinic keratosis count on skin-related quality of life: results from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial. ( Beatson, M; Chren, MM; Siegel, JA; Weinstock, MA, 2019) |
| "Inflammation of actinic keratoses (AK) was originally described with systemic 5-fluorouracil, and led to the development of topical fluorouracil." | 5.22 | Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis. ( Jemec, GBE; Peteln, I; Šuler Baglama, Š, 2022) |
| "Topical Fluorouracil 5% cream (5-FU) and 20% aminolevulinic acid (ALA)/ photodynamic therapy (PDT) are both FDA approved for the treatment of Actinic Keratosis (AK)." | 5.20 | A Controlled Comparison Study of Topical Fluourouracil 5% Cream Pre-Treatment of Aminolevulinic Acid/Photodynamic Therapy for Actinic Keratosis. ( Hamann, C; Tanghetti, EA; Tanghetti, M, 2015) |
| "Five per cent 5-fluorouracil (5-FU) cream is a well-established treatment for actinic keratosis (AK), and ingenol mebutate gel (IMB) is a novel topical field-directed therapy." | 5.20 | Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. ( Samorano, LP; Sanches, JA; Torezan, LA, 2015) |
| "The antimetabolite 5-fluorouracil (5-FU) is used for topical treatment of actinic keratosis." | 5.19 | Five percent 5-fluorouracil in a cream or for superficial peels in the treatment of advanced photoaging of the forearms: a randomized comparative study. ( Bagatin, E; Guimarães, CO; Miot, HA, 2014) |
| "The purpose of this study was to compare the efficacy of 5-fluorouracil (5-FU) with that of other treatments of actinic keratosis (AK)." | 5.01 | Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: A network meta-analysis. ( Cai, L; Li, Q; Tang, N; Wu, Y, 2019) |
| "Background Topical 5-fluorouracil (5-FU) is an antineoplastic antimetabolite used for the treatment of actinic keratosis." | 4.93 | 5-Fluorouracil-induced exacerbation of rosacea. ( Cohen, PR; Haddock, ES, 2016) |
| " The articles were selected following a MEDLINE database search of the combined terms fluorouracil, salicylic acid and actinic keratosis which represent the peer review publications of clinical studies that primarily investigate the use of Actikerall in AK." | 4.93 | Low-Dose 0.5% 5-Fluorouracil/10% Salicylic Acid Topical Solution in the Treatment of Actinic Keratoses. ( Azeredo, RR; Dirschka, T; Herranz, P; Morton, C; Roldán-Marín, R, 2016) |
| "Studies comparing 5-fluorouracil (5-FU), imiquimod, and photodynamic therapy with aminolevulinic acid (PDT-ALA) have evaluated the efficacy of destroying actinic keratosis (AK)." | 4.12 | A comparison of invasive squamous cell carcinoma greater than 1 year after treatment with 5-fluorouracil, imiquimod, or photodynamic therapy with aminolevulinic acid. ( Cheng, B; Etzkorn, JR; Giordano, CN; Higgins, HW; Miller, CJ; Shin, TM; Sobanko, JF; Veerabagu, S, 2022) |
| "Topical 5-fluorouracil (5-FU) is a valuable treatment of actinic keratosis (AK), but its use is limited by bothersome side effects." | 3.96 | Group clinic for chemoprevention of squamous cell carcinoma: a pilot study. ( Beatson, M; Landow, SM; Leader, N; Shaw, FM; Weinstock, MA, 2020) |
| "5%/salicylic acid 10% (5-FU/SA) topical solution has been included in the National Italian portfolio for lesion-directed treatment of grade I/II actinic keratosis (AKs) located on the face or scalp." | 3.96 | Treatment monitoring of 5-fluorouracil 0.5%/salicylic acid 10% lesion-directed therapy for actinic keratosis using dermoscopy and in-vivo reflectance confocal microscopy. ( Benati, E; Condorelli, A; Cornacchia, L; Guiducci, L; Lai, M; Longo, C; Mirra, M; Pampena, R; Pellacani, G; Peris, K; Raucci, M, 2020) |
| "We identified 5700 subjects who filled prescriptions for 5-fluorouracil or imiquimod for treatment of actinic keratosis in 2007." | 3.91 | Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study. ( Asgari, MM; Chren, MM; Friedman, GD; Neugebauer, R; Sokil, M; Su, KA; Zhu, Z, 2019) |
| "To assess the RCM accuracy, sensibility and specificity for actinic keratosis, considering as a gold standard the histopathological examination; as well as to evaluate the efficacy of 5% 5-fluorouracil treatment." | 3.88 | In vivo Confocal Laser Microscopy for monitoring of actinic keratosis treatment: a comparison with histopathologic assessment after treatment with topical 5% 5-fluorouracil. ( Hirata, SH; Ishioka, P; Lellis, RF; Maia, M; Rodrigues, SB, 2018) |
| "To non-invasively assess the pharmacodynamic changes induced by treatment with low dose 5-fluorouracil and 10% salicylic acid by means of RCM and high-definition OCT in field cancerization and actinic keratosis." | 3.83 | Treatment monitoring of 0.5% 5-fluorouracil and 10% salicylic acid in clinical and subclinical actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy. ( Alarcon, I; Malvehy, J; Montoya, J; Puig, S; Rodríguez-Azeredo, R, 2016) |
| "5%/salicylic acid 10% (5-FU/SA) in the treatment of isolated hyperkeratotic actinic keratosis lesions in Spain." | 3.81 | Cost-effectiveness analysis of 5-fluorouracil 0.5%/salicylic acid 10% in the treatment of actinic keratosis in Spain. ( Brosa, M; Ferrándiz, C; Nieves, D; Plazas, MJ; Puig-Peiró, R, 2015) |
| "Actinic keratosis is a lesion that develops in sun-exposed areas of the skin and is considered to be a precancerous condition or an early in situ squamous cell carcinoma." | 3.01 | Evaluating the Efficacy and Safety of 4% 5-Fluorouracil Cream in Patients with Actinic Keratosis: An Expert Opinion. ( Bégeault, N; Delarue, A; Heppt, MV; Stockfleth, E, 2023) |
| "Pretreatment with diclofenac for four weeks improved the clearance rate in one study (24." | 3.01 | Improving the efficacy of photodynamic therapy for actinic keratosis: A comprehensive review of pharmacological pretreatment strategies. ( Andersen, F; Bjerring, P; Haedersdal, M; Lerche, CM; Pihl, C, 2023) |
| "Calcipotriol suppressed skin cancer development in mice in a TSLP-dependent manner." | 2.84 | Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. ( Cornelius, LA; Cunningham, TJ; Demehri, S; Eliane, JP; Kopan, R; Manivasagam, S; Mirzaalian, H; Saavedra, AP; Schaffer, A; Tabacchi, M; Tuchayi, SM; Turkoz, A; Wallendorf, M, 2017) |
| "Actinic keratosis is caused by excessive lifetime sun exposure." | 2.82 | Topical Pharmacotherapy for Actinic Keratoses in Older Adults. ( Calzavara-Pinton, I; Calzavara-Pinton, P; Rossi, M; Rovati, C, 2022) |
| " 4% 5-FU qd q4wks recorded 65 adverse events and 30% application site skin irritation versus 71 events and 60% with 5% 5-FU bid q4wks." | 2.82 | Efficacy, Safety, and Tolerability of 4% 5-Fluorouracil Cream in a Novel Patented Aqueous Cream Containing Peanut Oil Once Daily Compared With 5% 5-Fluorouracil Cream Twice Daily: Meeting the Challenge in the Treatment of Actinic Keratosis. ( Dohil, MA, 2016) |
| "At 6-month posttreatment follow-up, recurrence of cleared lesions (no clinically visible lesions in treatment area) occurred in 39." | 2.80 | A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. ( Dirschka, T; Dominicus, R; Karl, L; Rodríguez, R; Simon, JC; Willers, C, 2015) |
| "Skin cancer is a broad term used to describe a number of different malignant indications of the skin." | 2.66 | Topical treatments for skin cancer. ( Boyle, GM; Cullen, JK; Parsons, PG; Simmons, JL, 2020) |
| "AKs must be considered an early squamous cell carcinoma (SCC) for their probable progression into invasive SCC." | 2.66 | Current therapies for actinic keratosis. ( Conforti, C; Corneli, P; di Meo, N; Dianzani, C; Farinazzo, E; Giuffrida, R; Magaton Rizzi, G; Moret, A; Zalaudek, I, 2020) |
| "In the future, the treatment of actinic keratosis can be more often done in primary health care." | 2.52 | [Diagnosis and treatment of actinic keratosis]. ( Isoherranen, K; Koskenmies, S; Overmark, M; Pitkänen, S; Saksela, O; Ylitalo, L, 2015) |
| " In the future, further studies are needed to evaluate the chance of adjusting drug dosage according to patients' and actinic keratoses features." | 1.72 | Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study. ( Bianchi, L; Campione, E; Cosio, T; Di Prete, M; Di Raimondo, C; Diluvio, L; Gaeta Shumak, R; Garofalo, V; Geraci, F; Lambiase, S; Lanna, C; Lozzi, F, 2022) |
| "5-Fluorouracil (5-FU) is an antineoplastic agent that is used topically to treat actinic keratoses." | 1.62 | Painful scrotal dermatitis secondary to topical 5-fluorouracil. ( Himes, RS; McKee, PH; Roberts, AA; Smith, RJ; Yi, JZ, 2021) |
| " Adverse reactions (ARs) were more common with cryotherapy (9." | 1.56 | Real-World Effectiveness and Safety of Field- and Lesion-Directed Treatments for Actinic Keratosis. ( Dunkelly-Allen, N; Feldman, SR; Hansen, JB; Larsson, T; Veverka, KA, 2020) |
| "Actinic keratoses (AKs) and squamous cell carcinoma in situ (SCCIS) are precursor lesions for cutaneous squamous cell carcinoma (cSCC), the second most common form of cancer." | 1.51 | Topical kinase inhibitors induce regression of cutaneous squamous cell carcinoma. ( Beer, J; D'Armas, S; Daifallah, AEM; Dentchev, T; Farag, AM; Hahn, J; Lee, V; Marshall, C; Sabry, HH; Seykora, F; Seykora, JT; Shankar, S; Yang, X, 2019) |
| " A novel semisolid dosage form enriched by NLC which is promising for topical treatment of skin cancers was developed." | 1.51 | QbD guided early pharmaceutical development study: Production of lipid nanoparticles by high pressure homogenization for skin cancer treatment. ( Aksu, B; Amasya, G; Badilli, U; Onay-Besikci, A; Tarimci, N, 2019) |
| "The cost of topical treatments for actinic keratosis (AK) has historically been evaluated in relation to the number of lesions requiring treatment or simply by the price of a single tube/sachet of the drug used." | 1.51 | Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions. ( Calzavara-Pinton, P; Hamon, P; Tanova, N, 2019) |
| "5% 5-fluorouracil solution in combination with 10% salicylic acid (low-dose 5-FU/SA) are mostly related to lesions appearing on the head and face." | 1.46 | Low-dose 5-fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and/or forearms - results of a non-interventional study. ( Hadshiew, I; Melzer, A; Prechtl, A; Reinhold, U, 2017) |
| "The incidence of non-melanoma skin cancer (NMSC), including actinic keratosis (AK), squamous cell carcinoma (SCC), Bowen's Disease (BD) and basal cell carcinoma (BCC), is increasing." | 1.42 | Field cancerization: from molecular basis to selective field-directed management of actinic keratosis. ( Philipp-Dormston, WG, 2015) |
| " Patients completed surveys monitoring adverse effects and tolerability." | 1.40 | The efficacy and safety of topical 5% 5-fluorouracil in renal transplant recipients for the treatment of actinic keratoses. ( Ingham, AI; Weightman, W, 2014) |
| "A number of effective treatments for actinic keratosis are available, including topical and lesion-directed therapies." | 1.36 | Case-based experience in the use of 5-fluorouracil cream 0.5% as monotherapy and in conjunction with glycolic acid peels for the treatment of actinic keratosis. ( Goldberg, DJ, 2010) |
| "For an improved treatment of actinic keratosis and squamous cell carcinoma, inhibitors of human DNA polymerase alpha (pol alpha) are developed by docking nucleoside phosphonate diphosphates into the active site of pol alpha." | 1.36 | Antitumor effects of guanosine-analog phosphonates identified by molecular modelling. ( Höltje, HD; Höltje, M; Korting, HC; Murruzzu, C; Natek, M; Reissig, HU; Schäfer-Korting, M; Schwanke, A; Zdrazil, B; Zuhse, R, 2010) |
| "Non-melanoma skin cancers, such as squamous cell carcinoma and basal cell carcinoma, also represent sun-related conditions that require early and aggressive treatment." | 1.36 | Case-based considerations in the treatment of actinic keratoses: utilizing combination or sequential therapy with 5-fluorouracil cream and destructive treatments. ( Goldsmith, A; Han, A; Marmur, ES; Penrose, C, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (6.17) | 29.6817 |
| 2010's | 102 (62.96) | 24.3611 |
| 2020's | 50 (30.86) | 2.80 |
| Authors | Studies |
|---|---|
| Hasan, ZU | 1 |
| Ahmed, I | 1 |
| Matin, RN | 1 |
| Homer, V | 1 |
| Lear, JT | 1 |
| Ismail, F | 1 |
| Whitmarsh, T | 1 |
| Green, AC | 1 |
| Thomson, J | 1 |
| Milligan, A | 1 |
| Hogan, S | 1 |
| Van-de-Velde, V | 1 |
| Mitchell-Worsford, L | 1 |
| Kentley, J | 1 |
| Gaunt, C | 1 |
| Jefferson-Hulme, Y | 1 |
| Bowden, SJ | 1 |
| Gaunt, P | 1 |
| Wheatley, K | 1 |
| Proby, CM | 1 |
| Harwood, CA | 2 |
| Mohney, L | 1 |
| Singh, R | 1 |
| Grada, A | 1 |
| Feldman, S | 1 |
| Kalil, CLPV | 1 |
| Reinehr, CPH | 1 |
| Bakos, RM | 2 |
| Calzavara-Pinton, P | 2 |
| Calzavara-Pinton, I | 1 |
| Rovati, C | 1 |
| Rossi, M | 1 |
| Supapannachart, KJ | 1 |
| Kwon, CW | 1 |
| Tushe, S | 1 |
| Guest, JL | 1 |
| Chen, SC | 3 |
| Yeung, H | 1 |
| Garofalo, V | 1 |
| Geraci, F | 1 |
| Di Prete, M | 1 |
| Lanna, C | 1 |
| Lozzi, F | 1 |
| Cosio, T | 1 |
| Lambiase, S | 1 |
| Gaeta Shumak, R | 1 |
| Di Raimondo, C | 1 |
| Diluvio, L | 1 |
| Bianchi, L | 1 |
| Campione, E | 1 |
| Ahmady, S | 3 |
| Jansen, MHE | 5 |
| Nelemans, PJ | 5 |
| Kessels, JPHM | 5 |
| Arits, AHMM | 2 |
| de Rooij, MJM | 1 |
| Essers, BAB | 4 |
| Quaedvlieg, PJF | 2 |
| Kelleners-Smeets, NWJ | 5 |
| Mosterd, K | 5 |
| Cheng, B | 1 |
| Veerabagu, S | 1 |
| Miller, CJ | 2 |
| Sobanko, JF | 1 |
| Shin, TM | 1 |
| Higgins, HW | 1 |
| Giordano, CN | 1 |
| Etzkorn, JR | 1 |
| Romero, MP | 1 |
| Posso, V | 1 |
| Ureña, V | 1 |
| Inada, N | 1 |
| Bagnato, V | 1 |
| Cabrera, F | 1 |
| Anand, S | 2 |
| Heusinkveld, LE | 1 |
| Cheng, CE | 1 |
| Lefatshe, L | 1 |
| De Silva, P | 1 |
| Hasan, T | 1 |
| Maytin, EV | 2 |
| Huisman, BW | 1 |
| Nené, LEH | 1 |
| Linders, FLL | 1 |
| Gambrah, TK | 1 |
| van der Kolk, TN | 1 |
| de Kam, ML | 1 |
| Bavinck, JNB | 1 |
| Burggraaf, J | 1 |
| Feiss, G | 1 |
| Rissmann, R | 1 |
| Šuler Baglama, Š | 1 |
| Peteln, I | 1 |
| Jemec, GBE | 1 |
| Worley, B | 3 |
| Harikumar, V | 3 |
| Reynolds, K | 3 |
| Dirr, MA | 3 |
| Christensen, RE | 3 |
| Anvery, N | 3 |
| Yi, MD | 3 |
| Poon, E | 3 |
| Alam, M | 3 |
| Junejo, MH | 1 |
| Demirel, S | 1 |
| Matin, R | 1 |
| Proby, C | 1 |
| Lampley, N | 1 |
| Rigo, R | 1 |
| Schlesinger, T | 1 |
| Rossi, AM | 1 |
| Arcuri, D | 1 |
| Ramchatesingh, B | 1 |
| Lagacé, F | 1 |
| Iannattone, L | 1 |
| Netchiporouk, E | 1 |
| Lefrançois, P | 1 |
| Litvinov, IV | 1 |
| Ha, NG | 1 |
| Lee, SH | 1 |
| Ha, DL | 1 |
| Park, KD | 1 |
| Jang, YH | 1 |
| Lee, WJ | 1 |
| Lee, SJ | 1 |
| Kim, JY | 1 |
| Nahm, W | 1 |
| Nichols, A | 1 |
| Rapoport, E | 1 |
| Kirsner, R | 1 |
| Badiavas, E | 1 |
| Wyant, W | 1 |
| Arthur, A | 1 |
| Shen, J | 1 |
| Pihl, C | 1 |
| Lerche, CM | 1 |
| Andersen, F | 1 |
| Bjerring, P | 1 |
| Haedersdal, M | 2 |
| Stockfleth, E | 5 |
| Heppt, MV | 5 |
| Bégeault, N | 1 |
| Delarue, A | 1 |
| Verhoeven, C | 1 |
| Claessens, Z | 1 |
| Lubeek, SFK | 1 |
| Schers, HJ | 1 |
| Navarrete-Dechent, C | 1 |
| Marghoob, AA | 2 |
| Marchetti, MA | 1 |
| Beatson, M | 4 |
| Siegel, JA | 4 |
| Chren, MM | 3 |
| Weinstock, MA | 9 |
| Cullen, JK | 1 |
| Simmons, JL | 1 |
| Parsons, PG | 1 |
| Boyle, GM | 1 |
| Merks, I | 1 |
| Dianzani, C | 1 |
| Conforti, C | 1 |
| Giuffrida, R | 1 |
| Corneli, P | 1 |
| di Meo, N | 1 |
| Farinazzo, E | 1 |
| Moret, A | 1 |
| Magaton Rizzi, G | 1 |
| Zalaudek, I | 1 |
| Steeb, T | 4 |
| Berking, C | 4 |
| Heuser, CL | 1 |
| Heuser, GG | 1 |
| Casagrande, J | 1 |
| de Fátima Pavan Zanella, J | 1 |
| Winkelmann, ER | 1 |
| West, CE | 1 |
| Kwatra, SG | 1 |
| Choi, J | 1 |
| Von Hoff, D | 1 |
| Booth, L | 1 |
| Dent, P | 1 |
| Cornejo, CM | 1 |
| Jambusaria-Pahlajani, A | 2 |
| Willenbrink, TJ | 1 |
| Schmults, CD | 2 |
| Arron, ST | 2 |
| Ruiz, ES | 1 |
| Pampena, R | 1 |
| Condorelli, A | 1 |
| Cornacchia, L | 1 |
| Guiducci, L | 1 |
| Raucci, M | 1 |
| Benati, E | 1 |
| Mirra, M | 1 |
| Peris, K | 3 |
| Lai, M | 1 |
| Pellacani, G | 3 |
| Longo, C | 2 |
| Payne, JE | 1 |
| Ghamrawi, RI | 1 |
| Lin, IJ | 1 |
| Feldman, SR | 6 |
| Raza, SA | 1 |
| Ali, FR | 1 |
| Leader, N | 1 |
| Shaw, FM | 1 |
| Landow, SM | 1 |
| Wessely, A | 2 |
| Schmitz, L | 2 |
| Heppt, F | 1 |
| Kirchberger, MC | 1 |
| Moore, AY | 2 |
| Nguyen, M | 1 |
| Moore, S | 1 |
| Koch, EAT | 1 |
| Wiest, LG | 1 |
| Hansen, JB | 1 |
| Larsson, T | 1 |
| Dunkelly-Allen, N | 1 |
| Veverka, KA | 1 |
| Sinclair, R | 1 |
| Baker, C | 1 |
| Spelman, L | 1 |
| Supranowicz, M | 1 |
| MacMahon, B | 1 |
| Salehi Farid, A | 1 |
| Niknam, S | 1 |
| Gholami, K | 1 |
| Tavakolpour, S | 1 |
| Teimourpour, A | 1 |
| Daneshpazhooh, M | 1 |
| Nili, A | 1 |
| Azizpour, A | 1 |
| Nasimi, M | 1 |
| Mahmoudi, H | 1 |
| Gilchrest, BA | 1 |
| Morgado-Carrasco, D | 1 |
| Fustà-Novell, X | 1 |
| Toll, A | 1 |
| Heron, CE | 1 |
| Means, AD | 2 |
| Leader, NF | 2 |
| Walker, JL | 2 |
| Pomerantz, H | 4 |
| Eisen, DB | 3 |
| Asgari, MM | 4 |
| Bennett, DD | 2 |
| Connolly, SM | 2 |
| Dellavalle, RP | 4 |
| Freeman, EE | 2 |
| Goldenberg, G | 2 |
| Leffell, DJ | 2 |
| Peschin, S | 2 |
| Sligh, JE | 2 |
| Wu, PA | 2 |
| Frazer-Green, L | 2 |
| Malik, S | 2 |
| Schlesinger, TE | 2 |
| Emmerich, VK | 1 |
| Cull, D | 1 |
| Kelly, KA | 1 |
| Oyen, EMM | 1 |
| Yi, JZ | 1 |
| Himes, RS | 1 |
| Smith, RJ | 1 |
| McKee, PH | 1 |
| Roberts, AA | 1 |
| Haddock, ES | 1 |
| Cohen, PR | 2 |
| Fine, JD | 1 |
| Dewan, A | 1 |
| Miller, JL | 1 |
| Sachar, M | 1 |
| Swetter, SM | 2 |
| Stricklin, GP | 1 |
| Qureshi, AA | 1 |
| DiGiovanna, JJ | 1 |
| Pei, S | 1 |
| Kaminska, ECN | 1 |
| Tsoukas, MM | 1 |
| Pillon, A | 1 |
| Gomes, B | 1 |
| Vandenberghe, I | 1 |
| Cartron, V | 1 |
| Cèbe, P | 1 |
| Blanchet, JC | 1 |
| Sibaud, V | 1 |
| Guilbaud, N | 1 |
| Audoly, L | 1 |
| Lamant, L | 1 |
| Kruczynski, A | 1 |
| Ulrich, M | 2 |
| Reinhold, U | 2 |
| Falqués, M | 1 |
| Rodriguez Azeredo, R | 1 |
| Ishioka, P | 1 |
| Maia, M | 1 |
| Rodrigues, SB | 1 |
| Lellis, RF | 1 |
| Hirata, SH | 1 |
| Salido Vallejo, R | 1 |
| Wenande, E | 1 |
| Erlendsson, AM | 1 |
| Neugebauer, R | 2 |
| Levandoski, KA | 1 |
| Zhu, Z | 2 |
| Sokil, M | 2 |
| Friedman, GD | 2 |
| Peuvrel, L | 1 |
| Saint-Jean, M | 1 |
| Quereux, G | 1 |
| Brocard, A | 1 |
| Le Moigne, M | 1 |
| Frénard, C | 1 |
| Khammari, A | 1 |
| Dreno, B | 2 |
| Yoon, J | 1 |
| Phibbs, CS | 1 |
| Chow, A | 1 |
| Li, AW | 1 |
| Lalor, LE | 1 |
| Bellodi Schmidt, F | 1 |
| Luu, M | 1 |
| Riha, M | 1 |
| Lohser, S | 1 |
| Tellez, A | 1 |
| Ishak, R | 1 |
| Karpinski, L | 1 |
| Sot, J | 1 |
| Hu, B | 1 |
| Denisyuk, A | 1 |
| Davis, SC | 1 |
| Kyei, A | 1 |
| Vidimos, A | 1 |
| Bosanac, SS | 1 |
| Nguyen, V | 1 |
| Bui, D | 1 |
| Sivamani, RK | 1 |
| Petersen Vitello Kalil, CL | 1 |
| Herman Reinehr, CP | 1 |
| de Mattos Milman, L | 1 |
| de Oliveira, ECV | 1 |
| da Motta, VRV | 1 |
| Pantoja, PC | 1 |
| Ilha, CSO | 1 |
| Magalhães, RF | 1 |
| Galadari, H | 1 |
| Leonardi, GR | 1 |
| Mazzella, C | 1 |
| Greco, V | 1 |
| Costa, C | 1 |
| Scalvenzi, M | 1 |
| Russo, D | 1 |
| Savastano, R | 1 |
| Staibano, S | 1 |
| Fabbrocini, G | 1 |
| Tanova, N | 1 |
| Hamon, P | 1 |
| Su, KA | 1 |
| Pavlis, J | 1 |
| Miteva, M | 1 |
| Wu, Y | 1 |
| Tang, N | 1 |
| Cai, L | 1 |
| Li, Q | 1 |
| Yang, X | 1 |
| Daifallah, AEM | 1 |
| Shankar, S | 1 |
| Beer, J | 1 |
| Marshall, C | 1 |
| Dentchev, T | 1 |
| Seykora, F | 1 |
| D'Armas, S | 1 |
| Hahn, J | 1 |
| Lee, V | 1 |
| Sabry, HH | 1 |
| Farag, AM | 1 |
| Seykora, JT | 1 |
| Jayaraj, R | 1 |
| Kumarasamy, C | 1 |
| Maarouf, M | 2 |
| Kromenacker, BW | 2 |
| Brucks, ES | 2 |
| Hendricks, A | 1 |
| Shi, VY | 2 |
| Kouloubis, N | 1 |
| van Pelt, HPA | 1 |
| Steijlen, PM | 1 |
| Robinson-Bostom, L | 1 |
| Iglesias-Puzas, A | 1 |
| Batalla, A | 1 |
| Suh-Oh, HJ | 1 |
| Flórez, A | 1 |
| Amasya, G | 1 |
| Aksu, B | 1 |
| Badilli, U | 1 |
| Onay-Besikci, A | 1 |
| Tarimci, N | 1 |
| Hendricks, AJ | 1 |
| Herms, F | 1 |
| Paugam, C | 1 |
| Kircik, LH | 1 |
| Gupta, AK | 1 |
| Paquet, M | 1 |
| Maughan, C | 1 |
| Lear, W | 1 |
| Samrao, A | 1 |
| Cockerell, CJ | 2 |
| Tallon, B | 1 |
| Turnbull, N | 1 |
| Comfere, NI | 1 |
| Ikediobi, ON | 1 |
| Peters, MS | 1 |
| el-Azhary, RA | 1 |
| Gibson, LE | 1 |
| Peserico, A | 1 |
| Neri, L | 1 |
| Calzavara Pinton, P | 1 |
| Catricalà, C | 1 |
| Pimpinelli, N | 1 |
| Ingham, AI | 1 |
| Weightman, W | 1 |
| Guimarães, CO | 1 |
| Miot, HA | 1 |
| Bagatin, E | 2 |
| Alomar, A | 1 |
| Simon, JC | 2 |
| Dominicus, R | 1 |
| Karl, L | 1 |
| Rodríguez, R | 1 |
| Willers, C | 2 |
| Dirschka, T | 3 |
| Hoover, WD | 1 |
| Jorizzo, JL | 1 |
| Clark, AR | 2 |
| Holbrook, J | 1 |
| Huang, KE | 1 |
| Nieves, D | 1 |
| Puig-Peiró, R | 1 |
| Ferrándiz, C | 1 |
| Plazas, MJ | 1 |
| Brosa, M | 1 |
| Fargnoli, MC | 1 |
| Philipp-Dormston, WG | 1 |
| Alarcon, I | 3 |
| Malvehy, J | 2 |
| Puig, S | 2 |
| Samorano, LP | 1 |
| Torezan, LA | 1 |
| Sanches, JA | 1 |
| Knackstedt, TJ | 1 |
| Quitadamo, M | 1 |
| Tolley, K | 1 |
| Kemmett, D | 1 |
| Thybo, S | 1 |
| Nasr, R | 1 |
| Smethurst, H | 1 |
| Szeimies, RM | 1 |
| Prechtl, A | 2 |
| Melzer, A | 2 |
| Hogan, D | 1 |
| Eilers, D | 1 |
| Jacob, SE | 1 |
| Warshaw, EM | 1 |
| Stricklin, G | 1 |
| Sidhu-Malik, N | 1 |
| Konnikov, N | 1 |
| Werth, VP | 1 |
| Keri, J | 1 |
| Lew, R | 2 |
| Sibbring, GC | 1 |
| Isoherranen, K | 1 |
| Koskenmies, S | 1 |
| Overmark, M | 1 |
| Ylitalo, L | 1 |
| Saksela, O | 1 |
| Pitkänen, S | 1 |
| van Rijsingen, MC | 1 |
| Seubring, I | 1 |
| Grutters, JP | 1 |
| Maessen-Visch, MB | 1 |
| Alkemade, HA | 1 |
| van Doorn, R | 1 |
| Groenewoud, H | 1 |
| van de Kerkhof, PC | 1 |
| van der Wilt, GJ | 1 |
| Gerritsen, MJ | 1 |
| Werner, RN | 1 |
| Jacobs, A | 1 |
| Rosumeck, S | 1 |
| Erdmann, R | 1 |
| Sporbeck, B | 1 |
| Nast, A | 1 |
| Montoya, J | 1 |
| Rodríguez-Azeredo, R | 1 |
| Tanghetti, EA | 1 |
| Hamann, C | 1 |
| Tanghetti, M | 1 |
| Taub, AF | 1 |
| Schieber, AC | 1 |
| Ortman, S | 1 |
| Liang, C | 1 |
| Callander, J | 1 |
| Ponnambath, N | 1 |
| Lebwohl, M | 1 |
| Tsui, M | 1 |
| Tajirian, A | 1 |
| Korgavkar, K | 2 |
| Lee, KC | 1 |
| Nguyen, HP | 1 |
| Rivers, JK | 1 |
| Herranz, P | 1 |
| Morton, C | 1 |
| Azeredo, RR | 1 |
| Roldán-Marín, R | 1 |
| Meeks, NM | 1 |
| Burden, JG | 1 |
| Carroll, BT | 1 |
| Hadshiew, I | 1 |
| Dohil, MA | 1 |
| Awan, S | 1 |
| Grant-Kels, JM | 1 |
| Graff, J | 1 |
| Cunningham, TJ | 1 |
| Tabacchi, M | 1 |
| Eliane, JP | 1 |
| Tuchayi, SM | 1 |
| Manivasagam, S | 1 |
| Mirzaalian, H | 1 |
| Turkoz, A | 1 |
| Kopan, R | 1 |
| Schaffer, A | 1 |
| Saavedra, AP | 1 |
| Wallendorf, M | 1 |
| Cornelius, LA | 1 |
| Demehri, S | 1 |
| Nissen, CV | 1 |
| Heerfordt, IM | 1 |
| Wiegell, SR | 1 |
| Mikkelsen, CS | 1 |
| Wulf, HC | 1 |
| Yentzer, B | 1 |
| Hick, J | 1 |
| Williams, L | 1 |
| Inabinet, R | 1 |
| Wilson, R | 1 |
| Camacho, FT | 1 |
| Russell, GB | 1 |
| Ulrich, C | 1 |
| Askew, DA | 1 |
| Mickan, SM | 1 |
| Soyer, HP | 1 |
| Wilkinson, D | 1 |
| Muston, D | 1 |
| Downs, A | 1 |
| Rives, V | 1 |
| Schmid-Wendtner, MH | 1 |
| Wendtner, CM | 1 |
| Sachs, DL | 1 |
| Kang, S | 1 |
| Hammerberg, C | 1 |
| Helfrich, Y | 1 |
| Karimipour, D | 1 |
| Orringer, J | 1 |
| Johnson, T | 1 |
| Hamilton, TA | 1 |
| Fisher, G | 1 |
| Voorhees, JJ | 1 |
| Leonard, N | 1 |
| Wilson, N | 1 |
| Calonje, JE | 1 |
| Teixeira, SP | 1 |
| Hassun, KM | 1 |
| Pereira, T | 1 |
| Michalany, NS | 1 |
| Talarico, S | 1 |
| Kaur, RR | 1 |
| Alikhan, A | 1 |
| Maibach, HI | 2 |
| Schlaak, M | 1 |
| Goldberg, DJ | 1 |
| Micali, G | 1 |
| Lacarrubba, F | 1 |
| Dinotta, F | 1 |
| Massimino, D | 1 |
| Nasca, MR | 1 |
| Shoimer, I | 1 |
| Rosen, N | 1 |
| Muhn, C | 1 |
| West, DA | 1 |
| Aires, DJ | 1 |
| Fenske, NA | 1 |
| Spencer, J | 1 |
| Adam, F | 1 |
| Stough, D | 1 |
| Bucko, AD | 1 |
| Vamvakias, G | 1 |
| Rafal, ES | 1 |
| Davis, SA | 1 |
| Schwanke, A | 1 |
| Murruzzu, C | 1 |
| Zdrazil, B | 1 |
| Zuhse, R | 1 |
| Natek, M | 1 |
| Höltje, M | 1 |
| Korting, HC | 1 |
| Reissig, HU | 1 |
| Höltje, HD | 1 |
| Schäfer-Korting, M | 1 |
| Han, A | 1 |
| Penrose, C | 1 |
| Goldsmith, A | 1 |
| Marmur, ES | 1 |
| Terushkin, V | 1 |
| Braga, JC | 1 |
| Dusza, SW | 1 |
| Scope, A | 1 |
| Busam, K | 1 |
| Gill, M | 1 |
| Halpern, AC | 1 |
| Huang, WW | 1 |
| Grossberg, AL | 1 |
| Gaspari, AA | 1 |
| Brodell, EE | 1 |
| Smith, E | 1 |
| Brodell, RT | 1 |
| Martin, G | 1 |
| Kerl, H | 1 |
| Zwingers, T | 1 |
| Woolery-Lloyd, H | 1 |
| Elsaie, ML | 1 |
| Avashia, N | 1 |
| Nikkhah, D | 1 |
| Abood, A | 1 |
| Watt, D | 1 |
| Al-Niaimi, F | 1 |
| Lyon, C | 1 |
| Ondo, AL | 1 |
| Padilla, RS | 1 |
| Miedler, JD | 1 |
| Kerner, JD | 1 |
| Steiner, RL | 1 |
| Mings, SM | 1 |
| Shanler, SD | 1 |
| Powers, R | 1 |
| Gordon, R | 1 |
| Roberts, K | 1 |
| Kovach, R | 1 |
| Sargen, M | 1 |
| Wanat, KA | 1 |
| Jambusaria, A | 1 |
| Rosenbach, M | 1 |
| Sobanko, J | 1 |
| Rahvar, M | 1 |
| Rhavar, M | 1 |
| Lamel, SA | 1 |
| Schmutz, JL | 1 |
| Trechot, P | 1 |
| Esmann, S | 1 |
| Jemec, GB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Value of Optical Coherence Tomography in Discrimination Between the Presence and Absence of Invasion in Clinical Actinic Keratosis[NCT06014697] | 75 participants (Anticipated) | Observational | 2023-03-01 | Active, not recruiting | |||
| Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study[NCT02281682] | Phase 4 | 624 participants (Actual) | Interventional | 2014-11-30 | Active, not recruiting | ||
| CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial[NCT00847912] | Phase 4 | 954 participants (Actual) | Interventional | 2009-06-26 | Completed | ||
| Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention: A Long-term (3 Years) Follow-up of Prospective, Randomized, Multicenter-clinical Trial[NCT03642535] | Phase 4 | 300 participants (Anticipated) | Interventional | 2018-08-30 | Recruiting | ||
| A Prospective Comparator Controlled Randomized Exploratory Study on the Efficacy of LAS 41005 Compared to Cryotherapy in Subjects With Hyperkeratotic Actinic Keratosis[NCT01358851] | Phase 2 | 67 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Evaluation of the Tolerability and Safety of 0.015% Ingenol Mebutate Gel Compared to 5% 5-fluorouracil Cream for the Treatment of Facial Actinic Keratosis: a Prospective Randomized Trial[NCT02242747] | 100 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil[NCT02938715] | 26 participants (Actual) | Interventional | 2016-10-31 | Completed | |||
| The Study of Plum-blossom Needling Enhancing Efficacy of Aminolevulinic Acid-photodynamic Therapy for Actinic Keratosis: a Randomized and Multi-center Clinical Trial[NCT03596619] | 250 participants (Anticipated) | Interventional | 2018-08-30 | Recruiting | |||
| The Role of 5-Fluorouracil in Post-Operative Scar Formation Following Direct Brow Ptosis Repair[NCT03219580] | Phase 3 | 50 participants (Anticipated) | Interventional | 2017-05-20 | Enrolling by invitation | ||
| The Role of Calcipotriol in Treatment of Pre-cancerous Skin Lesions[NCT02019355] | Early Phase 1 | 132 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Combination Topical 5-fluorouracil 5% / Calcipotriene 0.005% Cream for Treatment of in Situ and Superficially Invasive Squamous Cell Carcinoma of the Skin[NCT04839731] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2021-04-14 | Recruiting | ||
| Combination Calcipotriene 0.005% Foam and Fluorouracil 5% Cream for the Treatment of Actinic Keratoses on the Scalp[NCT03996252] | Early Phase 1 | 15 participants (Actual) | Interventional | 2019-07-01 | Terminated (stopped due to The study team was not able to start the study and they never completed the IRB submission, so the study was terminated.) | ||
| Calcipotriol Plus 5-Fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients[NCT04642287] | Phase 2 | 64 participants (Anticipated) | Interventional | 2026-01-31 | Not yet recruiting | ||
| Calcipotriol Plus 5-Flourouracil Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients[NCT04329221] | Phase 2 | 62 participants (Anticipated) | Interventional | 2026-01-01 | Not yet recruiting | ||
| Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population[NCT00696488] | Phase 4 | 20 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Imiquimod in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities[NCT03370406] | Phase 1 | 30 participants (Anticipated) | Interventional | 2018-08-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00847912)
Timeframe: date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years
| Intervention | participants (Number) |
|---|---|
| Arm 1: 5-fluorouracil | 182 |
| Arm 2: Placebo, Vehicle Control | 177 |
Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically. (NCT00847912)
Timeframe: From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years
| Intervention | years (Median) |
|---|---|
| Arm 1: 5-fluorouracil | 3.37 |
| Arm 2: Placebo, Vehicle Control | 3.52 |
Measure of adherence by MEMS caps and the % of total prescribed doses that were actually used (NCT00696488)
Timeframe: 12 weeks
| Intervention | percentage of prescribed doses (Mean) |
|---|---|
| Fluorouracil 0.5% | 86 |
44 reviews available for fluorouracil and Actinic Keratosis
| Article | Year |
|---|---|
Use of Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Systematic Review.
Topics: Acetamides; Calcitriol; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratosis, Actinic; Morpholi | 2022 |
Topical Pharmacotherapy for Actinic Keratoses in Older Adults.
Topics: Aged; Diclofenac; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Treatment Outcome | 2022 |
Combination of 5-Fluorouracil with Photodynamic Therapy: Enhancement of Innate and Adaptive Immune Responses in a Murine Model of Actinic Keratosis
Topics: Aminolevulinic Acid; Animals; Biomarkers; Disease Models, Animal; Fluorouracil; Immunity; Keratosis, | 2023 |
Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis.
Topics: Aged; Biomarkers; Drug Repositioning; Fluorouracil; Humans; Inflammation; Keratosis, Actinic; Middle | 2022 |
Treatment of actinic keratosis: a systematic review.
Topics: Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Skin Neoplasms; Treatment Ou | 2023 |
Treatment of actinic keratosis: a systematic review.
Topics: Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Skin Neoplasms; Treatment Ou | 2023 |
Treatment of actinic keratosis: a systematic review.
Topics: Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Skin Neoplasms; Treatment Ou | 2023 |
Treatment of actinic keratosis: a systematic review.
Topics: Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Skin Neoplasms; Treatment Ou | 2023 |
Field Therapy for Actinic Keratosis: A Structured Review of the Literature on Efficacy, Cost, and Adherence.
Topics: Aged; Fluorouracil; Humans; Keratosis, Actinic; Medicare; Photochemotherapy; Treatment Outcome; Unit | 2023 |
Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review.
Topics: Aminolevulinic Acid; Diclofenac; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemother | 2023 |
Improving the efficacy of photodynamic therapy for actinic keratosis: A comprehensive review of pharmacological pretreatment strategies.
Topics: Aminolevulinic Acid; Diclofenac; Fluorouracil; Humans; Keratosis, Actinic; Photochemotherapy; Photos | 2023 |
Evaluating the Efficacy and Safety of 4% 5-Fluorouracil Cream in Patients with Actinic Keratosis: An Expert Opinion.
Topics: Adult; Emollients; Expert Testimony; Fluorouracil; Humans; Keratosis, Actinic; Skin; Skin Neoplasms | 2023 |
Topical treatments for skin cancer.
Topics: Administration, Cutaneous; Antineoplastic Agents; Carcinoma, Basal Cell; Clinical Trials as Topic; D | 2020 |
Current therapies for actinic keratosis.
Topics: Aftercare; Carcinoma, Squamous Cell; Chemexfoliation; Cryotherapy; Curettage; Dermoscopy; Diclofenac | 2020 |
Field cancerization: Treatment.
Topics: Administration, Cutaneous; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Carcinogenesi | 2020 |
Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis.
Topics: Colchicine; Cryosurgery; Diterpenes; Fluorouracil; Humans; Immunosuppressive Agents; Keratosis, Acti | 2021 |
Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis.
Topics: Fluorouracil; Humans; Keratosis, Actinic; Photochemotherapy; Randomized Controlled Trials as Topic; | 2021 |
A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies.
Topics: Antineoplastic Agents; Diclofenac; Disease Progression; Diterpenes; Fluorouracil; Humans; Imiquimod; | 2021 |
Actinic Keratoses: Reconciling the Biology of Field Cancerization with Treatment Paradigms.
Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Transformation, Neo | 2021 |
Guidelines of care for the management of actinic keratosis.
Topics: Diclofenac; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy | 2021 |
Guidelines of care for the management of actinic keratosis: Executive summary.
Topics: Cryosurgery; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Practice Guidel | 2021 |
5-Fluorouracil-induced exacerbation of rosacea.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents; Disease Progression; Fluorouracil; Humans; K | 2016 |
Opportunities for laser-assisted drug delivery in the treatment of cutaneous disorders.
Topics: Administration, Cutaneous; Anesthetics, Local; Antineoplastic Agents; Cicatrix; Cosmetic Techniques; | 2017 |
Topical application of 5-fluorouracil 5 percent cream associated with severe neutropenia: discussion of a case and review of systemic reactions after topical treatment with 5-fluorouracil.
Topics: Administration, Cutaneous; Aged; Angioedema; Antimetabolites, Antineoplastic; Cheilitis; Fluorouraci | 2018 |
Actinic keratosis - review for clinical practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cry | 2019 |
Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: A network meta-analysis.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Cryosurgery; Dermatologic Agents; Fluoro | 2019 |
Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review.
Topics: Adjuvants, Immunologic; Aged; Aminolevulinic Acid; Aminoquinolines; Anti-Inflammatory Agents, Non-St | 2013 |
Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents.
Topics: Administration, Topical; Aminoquinolines; Cryotherapy; Diclofenac; Dose-Response Relationship, Drug; | 2013 |
Pharmacogenetics in dermatology: a patient-centered update.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo | 2013 |
Actinic keratosis: new concepts and therapeutic approaches for an ancestral condition.
Topics: Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cryotherapy; Electrocoagulation; Fluorour | 2014 |
Conventional treatment of actinic keratosis: an overview.
Topics: Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cryotherapy; Fluoro | 2015 |
New Topical Treatment Options for Actinic Keratosis: A Systematic Review.
Topics: Administration, Cutaneous; Aminoquinolines; Dermatologic Agents; Diterpenes; Drug Combinations; Faci | 2016 |
[Diagnosis and treatment of actinic keratosis].
Topics: Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Ag | 2015 |
New Methods for the Clinical Enhancement of Photodynamic Therapy.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Keratosis, Actinic; Photochemotherapy; Temper | 2015 |
Low-Dose 0.5% 5-Fluorouracil/10% Salicylic Acid Topical Solution in the Treatment of Actinic Keratoses.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; Humans; | 2016 |
Current perspective on actinic keratosis: a review.
Topics: Adult; Age Factors; Aged; Cost of Illness; Dermatologic Agents; Disease Progression; Female; Fluorou | 2017 |
Actinic keratoses.
Topics: Aged; Aminoquinolines; Carcinoma, Squamous Cell; Cryotherapy; Dermatology; Fluorouracil; Humans; Imi | 2009 |
Topical treatment of field cancerization.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Diclofenac; Fluorouraci | 2009 |
Effectiveness of 5-fluorouracil treatment for actinic keratosis--a systematic review of randomized controlled trials.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; H | 2009 |
Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Dermatologic Agents; Facial Dermatoses; Fluorou | 2010 |
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders.
Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic | 2009 |
Treating skin cancer with topical cream.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Diclofenac; | 2010 |
Actinic keratoses: past, present and future.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamou | 2010 |
Topical antineoplastic agents in the treatment of mucocutaneous diseases.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Diterpenes; Fluorouracil; Humans; I | 2011 |
Squamous cell carcinomas of the lower limbs in African American women.
Topics: Administration, Topical; Aged; Aged, 80 and over; Biopsy, Needle; Black or African American; Carcino | 2011 |
Systemic toxicity from occlusive therapy with topical 5-fluorouracil: a case report and review of the literature.
Topics: Abdominal Pain; Administration, Cutaneous; Antimetabolites, Antineoplastic; Chills; Diarrhea; Drug E | 2012 |
Randomized, vehicle-controlled trials of topical 5-fluorouracil therapy for actinic keratosis treatment: an overview.
Topics: Administration, Topical; Female; Fluorouracil; Humans; Keratosis, Actinic; Male; Middle Aged; Pharma | 2012 |
33 trials available for fluorouracil and Actinic Keratosis
| Article | Year |
|---|---|
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
Topics: Carcinoma, Squamous Cell; Feasibility Studies; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; | 2022 |
Short-Term Follow-Up of a Randomized Controlled Trial of 0.5% and 5% 5-Fluorouracil After Microneedling for Treatment of Facial Actinic Keratoses.
Topics: Face; Fluorouracil; Follow-Up Studies; Humans; Keratosis, Actinic; Treatment Outcome | 2022 |
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; S | 2022 |
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; S | 2022 |
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; S | 2022 |
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; S | 2022 |
Effects of increased actinic keratosis count on skin-related quality of life: results from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Cell Count; Chemoprevention; Dermatologic Agents; Double | 2019 |
A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherla
Topics: Aminolevulinic Acid; Cost-Benefit Analysis; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, | 2020 |
Peeling with 70% glicolic acid followed by 5% 5-fluorouracil as well as 5% 5-fluorouracil cream are effective methods for the treatment of actinic keratoses on upper limbs: A randomized clinical trial.
Topics: Administration, Topical; Fluorouracil; Humans; Keratosis, Actinic; Treatment Outcome; Upper Extremit | 2020 |
Comparing efficacy and safety of potassium hydroxide 5% solution with 5-fluorouracil cream in patients with actinic keratoses: a randomized controlled trial.
Topics: Fluorouracil; Humans; Hydroxides; Keratosis, Actinic; Potassium Compounds; Treatment Outcome | 2022 |
The Effect of Four Approaches to Treat Actinic Keratosis on the Health-Related QOL, as Assessed by the Skindex-29 and Actinic Keratosis QOL.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Diterpenes; Female; Fluorouracil; Humans; Imiquimod; K | 2021 |
Rate and Proportion of Malignant Skin Biopsies for Basal Cell and Squamous Cell Carcinoma on the Face and Ears After a Single Course of Topical 5-Fluorouracil: The Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Basal Cell; Carci | 2021 |
Treatment of Actinic Keratoses: A Randomized Split-Site Approach Comparison of Sequential 5-Fluorouracil and 5-Aminolevulinic Acid Photodynamic Therapy to 5-Aminolevulinic Acid Photodynamic Monotherapy.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Dermatologic Agents; Drug Therapy, Combination; Esthet | 2017 |
Use of reflectance confocal microscopy to evaluate 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of subclinical lesions of actinic keratosis: subanalysis of a Phase III, randomized, double-blind, vehicle-controlled trial.
Topics: Aged; Antimetabolites, Antineoplastic; Cohort Studies; Double-Blind Method; Female; Fluorouracil; Hu | 2018 |
Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Basa | 2018 |
5-Fluorouracil Enhances Protoporphyrin IX Accumulation and Lesion Clearance during Photodynamic Therapy of Actinic Keratoses: A Mechanism-Based Clinical Trial.
Topics: Apoptosis; Biomarkers; Biopsy; Fluorouracil; Heme; Humans; Keratosis, Actinic; Photochemotherapy; Ph | 2018 |
Randomized and controlled pilot study of the pragmatic use of mobile phone based follow up of actinic keratoses treated with topical 5-fluorouracil.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Phone Use; | 2018 |
Reducing unpleasant side effects of topical 5-Fluorouracil treatment for actinic keratosis: a randomized controlled trial.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Clobetasol; Double-Blind Method | 2020 |
Randomized Trial of Four Treatment Approaches for Actinic Keratosis.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Diterpenes; Female; Fluorouracil; Follow-Up Studies; G | 2019 |
Characteristics of Keratinocyte Carcinomas and Patients with Keratinocyte Carcinomas Following a Single 2-4 Week Course of Topical 5-fluorouracil on the Face and Ears.
Topics: Administration, Topical; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; D | 2019 |
Five percent 5-fluorouracil in a cream or for superficial peels in the treatment of advanced photoaging of the forearms: a randomized comparative study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Biomarkers; Biopsy; Chemexfoliation; Collagen Ty | 2014 |
A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Cryosurgery; Drug Combinations; Facial Dermatose | 2015 |
Efficacy of cryosurgery and 5-fluorouracil cream 0.5% combination therapy for the treatment of actinic keratosis.
Topics: Administration, Cutaneous; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined | 2014 |
Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial.
Topics: Administration, Topical; Diterpenes; Drug Tolerance; Facial Dermatoses; Fluorouracil; Follow-Up Stud | 2015 |
Efficacy of low-dose 5-fluorouracil/salicylic acid in actinic keratoses in relation to treatment duration.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; D | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Do | 2015 |
A Controlled Comparison Study of Topical Fluourouracil 5% Cream Pre-Treatment of Aminolevulinic Acid/Photodynamic Therapy for Actinic Keratosis.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Antimetabolites, Antineoplastic; Fluorouracil; Human | 2015 |
Validation of Photograph-Based Toxicity Score for Topical 5-Fluorouracil Cream Application.
Topics: Administration, Cutaneous; Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous C | 2016 |
Efficacy, Safety, and Tolerability of 4% 5-Fluorouracil Cream in a Novel Patented Aqueous Cream Containing Peanut Oil Once Daily Compared With 5% 5-Fluorouracil Cream Twice Daily: Meeting the Challenge in the Treatment of Actinic Keratosis.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Dermatitis, Contact; Double-Blind Me | 2016 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Pretreatment with 5-Fluorouracil Cream Enhances the Efficacy of Daylight-mediated Photodynamic Therapy for Actinic Keratosis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Combined Modality Therapy; | 2017 |
Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses.
Topics: Administration, Cutaneous; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Follow-Up St | 2009 |
Topical fluorouracil for actinic keratoses and photoaging: a clinical and molecular analysis.
Topics: Administration, Topical; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Administrat | 2009 |
Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid--pilot study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Drug Combinations; F | 2010 |
Fluorouracil cream 0.5% for actinic keratoses on multiple body sites: an 18-month open-label study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fl | 2010 |
Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofe | 2011 |
85 other studies available for fluorouracil and Actinic Keratosis
| Article | Year |
|---|---|
Validation of actinic keratosis diagnosis and treatment codes among veterans living with HIV.
Topics: Fluorouracil; HIV Infections; Humans; International Classification of Diseases; Keratosis, Actinic; | 2022 |
Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study.
Topics: Fluorouracil; Humans; Keratosis, Actinic; Prospective Studies; Salicylic Acid; Treatment Outcome | 2022 |
A comparison of invasive squamous cell carcinoma greater than 1 year after treatment with 5-fluorouracil, imiquimod, or photodynamic therapy with aminolevulinic acid.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; | 2022 |
Clinical and histopathological study of actinic keratosis treatment with photodynamic therapy VS 5-fluorouracil for face cancerization.
Topics: Aminolevulinic Acid; Fluorouracil; Humans; Keratosis, Actinic; Photochemotherapy; Photosensitizing A | 2022 |
No effect of topical digoxin and furosemide for patients with actinic keratosis.
Topics: Administration, Topical; Digoxin; Fluorouracil; Furosemide; Humans; Keratosis, Actinic | 2023 |
CorrespondenceShort shock or slow burn? Patient perspectives on treatment of actinic keratoses with 5-fluorouracil 5% cream monotherapy versus 5-fluorouracil plus calcipotriol combination therapy.
Topics: Calcitriol; Combined Modality Therapy; Fluorouracil; Humans; Keratosis, Actinic | 2023 |
Controlled Single Freezing Cryotherapy for Mild Facial Actinic Keratosis.
Topics: Cryotherapy; Fluorouracil; Freezing; Humans; Keratosis, Actinic | 2023 |
Keratinocyte Carcinoma Chemoprevention With a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin.
Topics: Carcinoma, Squamous Cell; Chemoprevention; Fluorouracil; Humans; Imiquimod; Keratinocytes; Keratosis | 2023 |
Needs and challenges among general practitioners in the management of actinic keratosis: a qualitative study.
Topics: Fluorouracil; General Practitioners; Humans; Keratosis, Actinic; Netherlands; Skin Neoplasms | 2023 |
Contemporary management of actinic keratosis.
Topics: Carcinoma, Squamous Cell; Cryotherapy; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photoche | 2021 |
Cash is king: the balance of costs and effectiveness of treatments for actinic keratosis.
Topics: Aminolevulinic Acid; Cost-Benefit Analysis; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, | 2020 |
A novel plant-derived compound is synergistic with 5-fluorouracil and has increased apoptotic activity through autophagy in the treatment of actinic keratoses.
Topics: Autophagy; Fluorouracil; Humans; Keratosis, Actinic; Phytochemicals | 2022 |
Treatment monitoring of 5-fluorouracil 0.5%/salicylic acid 10% lesion-directed therapy for actinic keratosis using dermoscopy and in-vivo reflectance confocal microscopy.
Topics: Dermoscopy; Fluorouracil; Humans; Keratosis, Actinic; Microscopy, Confocal; Salicylic Acid | 2020 |
Utilization of an Online Cash-Pay Pharmacy for Topical 5-Fluorouracil Prescriptions in Older Patients.
Topics: Administration, Topical; Age Distribution; Age Factors; Aged; Aged, 80 and over; Cross-Sectional Stu | 2020 |
Comparison of efficacy of field treatments for actinic keratoses.
Topics: Adult; Aminolevulinic Acid; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photoch | 2020 |
Group clinic for chemoprevention of squamous cell carcinoma: a pilot study.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemopreve | 2020 |
Cyclic calcipotriene 0.005% foam and 1% 5-fluorouracil cream after cryotherapy in treatment of hyperkeratotic actinic keratosis: A retrospective study.
Topics: Calcitriol; Cryotherapy; Dermatologic Agents; Drug Administration Schedule; Fluorouracil; Humans; Im | 2021 |
Real-World Effectiveness and Safety of Field- and Lesion-Directed Treatments for Actinic Keratosis.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents; Combined Modality Therapy; Cryotherapy; Dite | 2020 |
RF-New Evidence in Favor of 5-Fluorouracil in the Treatment of Actinic Keratosis.
Topics: Fluorouracil; Humans; Keratosis, Actinic; Photochemotherapy; Photosensitizing Agents | 2021 |
Ingenol Mebutate and the Treatment of Actinic Keratosis.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Clinical Trials as Topic; Diterpenes; Fluorouracil; H | 2021 |
Patient assessment of 5-fluorouracil and imiquimod for the treatment of actinic keratoses: a retrospective study of real-world effectiveness.
Topics: Aminoquinolines; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Retrospective Studies; Treatme | 2022 |
Patient-reported skin reactions to 5% 5-fluorouracil in treatment of actinic keratosis.
Topics: Fluorouracil; Humans; Keratosis, Actinic; Patient Reported Outcome Measures | 2021 |
Painful scrotal dermatitis secondary to topical 5-fluorouracil.
Topics: Administration, Topical; Aged; Drug Eruptions; Fluorouracil; Humans; Keratosis, Actinic; Male; Pain; | 2021 |
Occurrence of Acute Cerebellar Syndrome After Topical Application of Fluorouracil.
Topics: Acute Disease; Administration, Topical; Cerebellar Diseases; Fluorouracil; Humans; Immunosuppressive | 2017 |
5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Double | 2017 |
5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Double | 2017 |
5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Double | 2017 |
5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Double | 2017 |
Actinic keratosis modelling in mice: A translational study.
Topics: Animals; Dermoscopy; Disease Models, Animal; Fluorouracil; Humans; Immunosuppressive Agents; Keratos | 2017 |
In vivo Confocal Laser Microscopy for monitoring of actinic keratosis treatment: a comparison with histopathologic assessment after treatment with topical 5% 5-fluorouracil.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorou | 2018 |
Imiquimoid 5%: In Pursuit of New Treatment Regimens for Actinic Keratosis.
Topics: Clinical Protocols; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic | 2018 |
A real-world, community-based cohort study comparing the effectiveness of topical fluorouracil versus topical imiquimod for the treatment of actinic keratosis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Cohort Studies | 2018 |
5-fluorouracil chemowraps for the treatment of multiple actinic keratoses.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Dermatologic Agents; Drug Administration Schedul | 2017 |
A pediatric case of squamous cell cancer in situ in the setting of sclerodermatous graft-versus-host disease and voriconazole treatment.
Topics: Administration, Topical; Antifungal Agents; Bone Marrow Transplantation; Carcinoma, Squamous Cell; D | 2018 |
Reflectance confocal microscopy: a crucial role for actinic keratosis treatment monitoring.
Topics: Fluorouracil; Humans; Keratosis, Actinic; Lasers; Microscopy, Confocal | 2018 |
Combination Therapies: Laser-Assisted Delivery of 5-Fluorouracil.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Dermatologic Agents; Facial Dermatoses; Female; | 2019 |
Management of clinical and subclinical actinic keratoses with histological and immunohistochemical assessments by confocal microscopy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Diclofenac; Fluorouracil; | 2018 |
Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions.
Topics: Administration, Topical; Aminolevulinic Acid; Cohort Studies; Cost of Illness; Diclofenac; Diterpene | 2019 |
Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study.
Topics: Administration, Cutaneous; Aged; California; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Compar | 2019 |
SnapshotDx Quiz: June 2017.
Topics: Fluorouracil; Genes, p53; Humans; Keratosis, Actinic; Mutation; Ultraviolet Rays | 2017 |
Topical kinase inhibitors induce regression of cutaneous squamous cell carcinoma.
Topics: Administration, Topical; Animals; Carcinoma, Squamous Cell; Dasatinib; Fluorouracil; Humans; Imidazo | 2019 |
Conceptual, statistical and clinical interpretation of results from: Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis.
Topics: Cryosurgery; Fluorouracil; Humans; Keratosis, Actinic | 2019 |
0.5% 5-Fluorouracil/10% Salicylic Acid for the Treatment of Distal Actinic Keratoses Under Daily Practice Conditions
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Dermatologic Agents; Drug Combinations; Extremit | 2019 |
QbD guided early pharmaceutical development study: Production of lipid nanoparticles by high pressure homogenization for skin cancer treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line; Drug Compounding; Drug Delivery Systems; Drug D | 2019 |
5-fluorouracil-induced erythema and transepidermal water loss associated with complete actinic keratosis resolution.
Topics: Aged; Aged, 80 and over; Body Water; Epidermis; Erythema; Female; Fluorouracil; Humans; Keratosis, A | 2019 |
Conceptual, statistical and clinical interpretation of results from: Cryosurgery combined with topical interventions for actinic keratosis: reply from the authors.
Topics: Cryosurgery; Fluorouracil; Humans; Keratosis, Actinic | 2019 |
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cost-Benefit Analysis; Cryotherapy; | 2019 |
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cryotherapy; Dermatologic Agents; Fl | 2019 |
Addressing the Challenges of Treating Actinic Keratosis
Topics: Dermatologic Agents; Disease Progression; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, Ac | 2019 |
Acute angioedema response to topical 5-fluorouracil therapy.
Topics: Administration, Topical; Aged; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Antimetabolites | 2013 |
5% fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Bandages; Carcinoma, Squamous Cell; Fluo | 2013 |
Key Opinion Leader (KOL) Consensus for actinic keratosis management in Italy: the AKTUAL Workshop.
Topics: Aminoquinolines; Carcinoma, Squamous Cell; Case Management; Clinical Trials as Topic; Cryosurgery; D | 2013 |
The efficacy and safety of topical 5% 5-fluorouracil in renal transplant recipients for the treatment of actinic keratoses.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Keratosis, Actinic | 2014 |
Cost-effectiveness analysis of 5-fluorouracil 0.5%/salicylic acid 10% in the treatment of actinic keratosis in Spain.
Topics: Antimetabolites, Antineoplastic; Cost-Benefit Analysis; Cryotherapy; Decision Support Techniques; Dr | 2015 |
Field cancerization: from molecular basis to selective field-directed management of actinic keratosis.
Topics: Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Ag | 2015 |
In vivo reflectance confocal microscopy characterization of field-directed 5-fluorouracil 0.5%/salicylic acid 10% in actinic keratosis.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dermatologic Agen | 2015 |
Imiquimod induces sustained remission of actinic damage: a case report spanning one decade of observation.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Fluorouracil | 2015 |
A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Topics: Cost-Benefit Analysis; Cryotherapy; Diclofenac; Diterpenes; Dose-Response Relationship, Drug; Fluoro | 2016 |
Real-life Data on Patient Characteristics, Cost and Effectiveness of Field-directed Treatment for Actinic Keratoses: An Observational Study.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Cost-Benefit Analysis; Dermatologic A | 2016 |
Methods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum.
Topics: Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Cryotherapy; Curettage; Cyclooxyg | 2015 |
Treatment monitoring of 0.5% 5-fluorouracil and 10% salicylic acid in clinical and subclinical actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy.
Topics: Administration, Topical; Dermoscopy; Drug Administration Schedule; Drug Therapy, Combination; Female | 2016 |
Sequential Curettage, 5-Fluorouracil, and Photodynamic Therapy for Field Cancerization of the Scalp and Face in Solid Organ Transplant Recipients.
Topics: Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Ther | 2016 |
Pemphigus foliaceus induced by topical 5-fluorouracil.
Topics: Aged; Female; Fluorouracil; Fusidic Acid; Humans; Hydrocortisone; Keratosis, Actinic; Pemphigus; Ste | 2016 |
Actinic Keratosis.
Topics: Female; Fluorouracil; Humans; Keratosis, Actinic; Male; Skin | 2016 |
Cicatricial Ectropion With Topical 5% Fluorouracil Cream.
Topics: Administration, Cutaneous; Aged, 80 and over; Antimetabolites, Antineoplastic; Cicatrix; Ectropion; | 2016 |
Actikerall™ (5-Fluorouracil 0.5% and Salicylic Acid 10%) Topical Solution for Patient-directed Treatment of Actinic Keratoses.
Topics: Administration, Topical; Clinical Trials as Topic; Drug Combinations; Fluorouracil; Humans; Keratosi | 2016 |
Fluorouracil-Induced Reactive Follicular Squamous Cell Carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Facial Neoplasms; Fluorouracil; For | 2016 |
Low-dose 5-fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and/or forearms - results of a non-interventional study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorour | 2017 |
Whose practice is this anyway? To conform or not to conform.
Topics: Antimetabolites, Antineoplastic; Beneficence; Clinical Decision-Making; Cryosurgery; Dermatology; Di | 2016 |
An economic evaluation of topical treatments for actinic keratosis.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Cost-Benefit | 2009 |
Intensified inflammatory reaction of actinic keratoses after single application of topical 5-fluorouracil in a patient treated with nilotinib for chronic myeloid leukemia.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents; Dermatologic Agents; Drug Therapy, Combinati | 2009 |
Squamomelanocytic tumor: an unusual and distinctive entity of uncertain biological potential.
Topics: Aged; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Immunohistochemistry; Keratosis, Actini | 2009 |
5-Fluorouracil superficial peel for multiple actinic keratoses.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Chemexfoliation; Drug Combi | 2009 |
Case-based experience in the use of 5-fluorouracil cream 0.5% as monotherapy and in conjunction with glycolic acid peels for the treatment of actinic keratosis.
Topics: Aged; Chemexfoliation; Female; Fluorouracil; Glycolates; Humans; Keratolytic Agents; Keratosis, Acti | 2010 |
Current management of actinic keratoses.
Topics: Administration, Cutaneous; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic | 2010 |
Treatment of actinic keratoses with topical fluorouracil.
Topics: Administration, Topical; Aged; Antimetabolites; Fluorouracil; Humans; Keratosis, Actinic; Male | 2010 |
Antitumor effects of guanosine-analog phosphonates identified by molecular modelling.
Topics: Adenine; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Fluorouracil; HT29 Cells | 2010 |
Case-based considerations in the treatment of actinic keratoses: utilizing combination or sequential therapy with 5-fluorouracil cream and destructive treatments.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Basal Cell; Carcinoma, Squamous | 2010 |
Agreement on the clinical diagnosis and management of cutaneous squamous neoplasms.
Topics: Algorithms; Aminoquinolines; Biopsy; Carcinoma in Situ; Carcinoma, Squamous Cell; Cryosurgery; Curet | 2010 |
Actinic keratosis. Patient-based approaches to adverse event management.
Topics: Administration, Topical; Aminoquinolines; Combined Modality Therapy; Cryotherapy; Dermatologic Agent | 2010 |
Exacerbation of seborrheic dermatitis by topical fluorouracil.
Topics: Administration, Topical; Aged; Aged, 80 and over; Dermatitis, Seborrheic; Dermatologic Agents; Disea | 2011 |
Prospective, case-based assessment of sequential therapy with topical Fluorouracil cream 0.5% and ALA-PDT for the treatment of actinic keratosis.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Drug Therapy, Combination; Fl | 2011 |
Cicatricial ectropion: a complication of topical 5-fluorouracil.
Topics: Administration, Topical; Aged, 80 and over; Cicatrix; Ectropion; Facial Dermatoses; Fluorouracil; Fo | 2012 |
Resolving actinic keratoses: an expected side-effect of capecitabine therapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidin | 2012 |
Treatment-refractory actinic keratoses successfully treated using simultaneous combination topical 5-fluorouracil cream and imiquimod cream: a case-control study.
Topics: Aged; Aged, 80 and over; Aminoquinolines; Analysis of Variance; Antimetabolites, Antineoplastic; Ant | 2012 |
Symmetrical drug-related intertriginous and flexural exanthema secondary to topical 5-fluorouracil.
Topics: Administration, Cutaneous; Drug Eruptions; Exanthema; Fluorouracil; Hand Dermatoses; Humans; Immunos | 2012 |
[Resolution of actinic keratosis with capecetabin].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorou | 2012 |
Patients' perceptions of topical treatments of actinic keratosis.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Diclofenac | 2014 |